Victory Capital Management Inc. Has $7.04 Million Stake in STAAR Surgical (NASDAQ:STAA)

Victory Capital Management Inc. lifted its stake in shares of STAAR Surgical (NASDAQ:STAA) by 16.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 189,481 shares of the medical instruments supplier’s stock after purchasing an additional 27,143 shares during the quarter. Victory Capital Management Inc.’s holdings in STAAR Surgical were worth $7,039,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of STAA. Van ECK Associates Corp boosted its stake in shares of STAAR Surgical by 12.7% during the third quarter. Van ECK Associates Corp now owns 3,478 shares of the medical instruments supplier’s stock valued at $129,000 after purchasing an additional 393 shares in the last quarter. Sei Investments Co. grew its holdings in STAAR Surgical by 2.7% during the 2nd quarter. Sei Investments Co. now owns 15,087 shares of the medical instruments supplier’s stock worth $718,000 after acquiring an additional 394 shares during the last quarter. Creative Planning increased its position in STAAR Surgical by 8.0% in the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock valued at $205,000 after acquiring an additional 408 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of STAAR Surgical by 3.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 11,343 shares of the medical instruments supplier’s stock valued at $540,000 after acquiring an additional 418 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC lifted its holdings in shares of STAAR Surgical by 2.3% during the second quarter. Linden Thomas Advisory Services LLC now owns 20,721 shares of the medical instruments supplier’s stock worth $987,000 after purchasing an additional 469 shares during the period. 96.70% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

STAA has been the subject of several recent research reports. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Stifel Nicolaus decreased their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, August 26th. Finally, Canaccord Genuity Group dropped their price target on shares of STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, STAAR Surgical currently has a consensus rating of “Hold” and a consensus price target of $43.33.

STAAR Surgical Stock Performance

NASDAQ:STAA opened at $26.63 on Friday. STAAR Surgical has a 52-week low of $25.88 and a 52-week high of $52.68. The firm has a market capitalization of $1.31 billion, a price-to-earnings ratio of 60.52 and a beta of 0.61. The stock has a fifty day moving average of $30.99 and a 200 day moving average of $36.81.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.